Last updated: July 14, 2026
Every major CIED manufacturer uses its own nomenclature, technical standards, and communication protocols to describe similar device features. This creates semantic interoperability barriers when clinicians aggregate data across vendors. The Heart Rhythm Society has documented that these proprietary systems prevent shared meaning even when the underlying clinical data is identical. Structural standards such as HL7 v2 and CDA organize data into common formats. Even so, one system may record a condition under one label while another uses a proprietary internal code, breaking downstream clinical decision support entirely.
The quantified consequences are significant. A 2026 cross-manufacturer analysis of 2,659 rhythm episodes from 1,710 patients implanted with ICMs from Medtronic, Biotronik, Abbott, and Boston Scientific found that 32.9% of episodes in AI-equipped devices were non-actionable. One major driver of this figure is R-wave undersensing in cardiac pause events. The device fails to detect a heartbeat and misinterprets the signal as a clinical pause, producing high false-positive rates for this episode type.
These errors carry financial consequences too. When organizations fail to actively pull data or ensure patient transmissions in multi-vendor remote monitoring programs, they lose both clinical visibility and the ability to bill for services. That loss of visibility often surfaces late. In long-duration cardiovascular programs with fragmented data from multiple device generations, failures often surface only at database lock, when longitudinal records already have gaps or attribution errors. Those same gaps then trigger billing rejections for remote monitoring CPT codes such as 93298, 93299, and 99454.
Rhythm360 addresses cross-manufacturer data fragmentation by ingesting API, HL7, XML, and unstructured PDF data through computer vision and AI-powered gap-filling. Redundant OEM data feeds maintain continuity when any single manufacturer server goes down. The result is a single normalized record for every patient regardless of device brand.
The table below shows how Rhythm360 resolves each OEM limitation category, from transmission delivery to billing documentation.
| Data Type | OEM Portal Limitation | Rhythm360 Accuracy | Clinical Impact |
|---|---|---|---|
| Overall Transmission Delivery | Siloed per manufacturer; gaps on server outage | >99.9% transmissibility via redundant feeds | No missed transmissions due to OEM downtime |
| Critical Alert Triage | Unfiltered OEM alerts; high non-actionable volume | AI triage reduces non-actionable noise; 80% faster critical response | Earlier intervention for VT, VF, new-onset AFib |
| Unstructured PDF / Legacy Data | Not machine-readable across portals | Computer vision OCR normalization | Complete longitudinal record; no manual transcription |
| CPT Billing Documentation | Manual compilation across portals; rejection risk | Automated documentation aligned to CPT requirements | Reduced claim rejections; up to 300% revenue improvement |
The University of Chicago Medicine (UCM) implemented Rhythm360 to consolidate cardiovascular remote monitoring across its CIED and heart failure populations. UCM reviewed more than 73,000 reports annually through Rhythm360 in calendar year 2025, averaging more than 18,000 reports per quarter. Gaurav A. Upadhyay, MD, FACC, FHRS, at UCM, noted: "That was a big piece for us, to have an integrated review of data from trained personnel."
See how UCM-style results are possible for your practice by requesting a Rhythm360 walkthrough.
Results like UCM's are backed by a wave of new standards designed to fix semantic mismatches at the source.
Several 2025 to 2026 standards updates are reshaping the baseline for semantic consistency in cardiac device data exchange.
Rhythm360 maps these evolving standards into normalized outputs. As nomenclature and FHIR profiles advance, the platform's data pipeline stays aligned with current regulatory and clinical requirements without manual reconfiguration by clinic staff.
Standards adoption alone does not eliminate integration failures, though. Three recurring failure modes still persist in multi-vendor cardiac data pipelines today.
Rhythm360's redundant OEM data feeds address network-loss failures by maintaining an independent data pathway when any single manufacturer server is unavailable. AI-powered extrapolation fills gaps created by retroactive ingestion delays. The platform's alert triage layer also applies a consistent interpretation framework across all manufacturer outputs to reduce the semantic inconsistency that drives false positives.
Even with advanced manufacturer AI, a substantial portion of cross-manufacturer transmitted episodes from ICMs are either non-actionable or indeterminate, based on 2026 analyses of episodes across four manufacturers. Vendor-neutral platforms that apply a standardized interpretation layer on top of OEM outputs reduce this burden by filtering noise before it reaches the clinical review queue.
Rhythm360 achieves this same >99.9% transmissibility rate mentioned earlier across all connected manufacturers. Following Rhythm360 implementation at UCM, Gaurav A. Upadhyay, MD, FACC, FHRS, observed: "We have improved billing and accountability for our patients after the integration." Bi-directional EHR integration with Epic, Cerner, Athenahealth, eClinicalWorks, and Greenway Health lets normalized transmission data flow directly into the patient record without manual transcription. Automated CPT documentation then closes the billing gaps that fragmented portals routinely create. Remote monitoring programs often leave revenue on the table due to gaps in patient engagement rather than billing errors alone, making proactive unified workflows necessary to capture revenue under 2026 CMS code updates that expand eligibility for transmissions occurring 2 to 15 days per month.
Unfiltered cross-manufacturer transmission volume causes alert fatigue directly. Arnaud Rosier, MD, PhD, electrophysiologist and co-founder of Implicity, stated: "Remote monitoring only works if clinicians can trust the alerts they receive. When a large share of those alerts are non-actionable, the burden is not just operational, it diverts valuable clinical time from patients who may truly need attention."
Rhythm360's AI-powered alert triage system filters non-actionable noise and prioritizes clinically significant events such as new-onset atrial fibrillation, ventricular tachycardia, lead malfunction, and ERI/RRT indicators. The platform reduces critical alert response times by up to 80% compared to manual multi-portal workflows. Optional 24/7/365 oversight by certified cardiac technicians (CCTs) supervised by physicians adds a human review layer for high-acuity events. The HIPAA-compliant mobile application lets clinicians review transmissions, sign reports, and coordinate care from any location, eliminating the need for a fixed workstation during on-call coverage.
At UCM, high dismissal rates in CIED monitoring reflect structural features of safety-first remote monitoring, since most OEM-generated alerts prove non-actionable across the practice's full report volume. A platform that normalizes and triages this volume without losing clinically significant signals becomes an operational requirement for any high-volume cardiology program.
Redundant OEM data feeds create a backup pathway for each manufacturer connection. When one server goes down, the backup feed keeps transmissions flowing so clinicians never lose visibility into a patient's device data. This design is what allows near-complete transmission reliability even during vendor-side outages, rather than relying on a single point of failure per manufacturer.
R-wave undersensing is the main culprit behind false pause alerts. The device misses an actual heartbeat signal and interprets the gap as a clinical pause event. Ectopy, oversensing, and sinus arrhythmias contribute as well, and their relative impact varies by manufacturer and device model. A standardized interpretation layer applied across OEM outputs catches these patterns before they reach a clinician's queue.
Codes 93298, 93299, 99454, and 99457 depend on documentation pulled from multiple manufacturer portals. When a transmission is missed, delayed, or logged in an incompatible format, the paper trail required to bill that code goes missing too. Automated, cross-manufacturer documentation closes this gap by compiling the required records the moment a transmission arrives, rather than after the fact.
Rhythm360 logs every data source and every correction made during gap-filling or extrapolation. Clinicians can trace back any data point to its origin, which matters when a decision hinges on whether a reading came from a live transmission or an AI-filled gap. This transparency is what lets staff trust a normalized record instead of treating it as a black box.
Fragmented OEM portals are a documented source of missed arrhythmias, alert fatigue, billing rejections, and compliance exposure. Cross-manufacturer cardiac device data integration accuracy in 2026 is measurable, and the gap between siloed proprietary portals and a unified vendor-neutral platform shows up in clinical outcomes, staff hours, and captured revenue. Rhythm360 closes that gap through redundant data feeds, computer vision, and AI-powered gap-filling, normalizing data from Medtronic, Boston Scientific, Abbott, Biotronik, and other manufacturers into one source of truth with bi-directional EHR integration and automated CPT documentation.
Practices that invest in unified cardiac data infrastructure now position themselves for a 2026 regulatory environment shaped by FHIR US Core STU 9.0.0, EN ISO/IEEE 11073-10103:2025, and expanding CMS remote monitoring eligibility. They also deliver the faster, more reliable care their patients need.
Schedule a demo to see how Rhythm360 closes the accuracy gap across every manufacturer platform your practice manages.
